Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus by Rosenson, Robert S. et al.
Achievement of Lipid Targets with the Combination
of Rosuvastatin and Fenofibric Acid in Patients with Type 2
Diabetes Mellitus
Robert S. Rosenson & Dawn M. Carlson &
Maureen T. Kelly & Carolyn M. Setze & Boaz Hirshberg &
James C. Stolzenbach & Laura A. Williams
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Objective The objective of this study was to assess the
proportion of patients with type 2 diabetes mellitus (T2DM)
attaining individual and combined targets of low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglycerides (TG), non-HDL-C, and
apolipoprotein B (ApoB) after treatment with rosuvastatin
(R) + fenofibric acid (FA) compared with corresponding-
dose R monotherapy.
Methods This post hoc analysis evaluated data from the
T2DM subset of patients with mixed dyslipidemia
(LDL-C ≥130 mg/dL, HDL-C <40/50 mg/dL in men/
women, and TG ≥150 mg/dL) from 2 randomized studies.
Patients included in the analysis (N=456) were treated with
R (5, 10, or 20 mg), FA 135 mg, or R (5, 10, or 20 mg) + FA
135 mg for 12 weeks. Attainment of LDL-C <100 mg/dL,
HDL-C >40/50mg/dL inmen/women, TG <150mg/dL,non-
HDL-C <130 mg/dL, ApoB <90 mg/dL, and the combined
targets of these parameters was assessed.
Results Treatment with R + FA resulted in a significantly
higher proportion of patients achieving optimal levels of
HDL-C (46.8% vs. 20.8%, P=0.009 for R 10 mg + FA),
TG (60.0% vs. 34.0%, P=0.02 for R 10 mg + FA; 54.0%
vs. 26.4%, P=0.005 for R 20 mg + FA), non-HDL-C
(55.1% vs. 36.4%, P=0.04 for R 5 mg + FA), ApoB (58.0%
vs. 36.4%, P=0.02 for R 5 mg + FA); and the combined
targets of LDL-C, HDL-C, and TG (28.3% vs. 8.3%, P=
0.02 for R 10 mg + FA) and all 5 parameters (26.1% vs.
8.3%, P=0.03 for R 10 mg + FA) than corresponding-dose
R monotherapies.
Conclusions A significantly greater proportion of T2DM
patients achieved individual and combined lipid targets
when treated with the combination of R + FA than
corresponding-dose R monotherapies.
Key words Fibrates.Statins.Dyslipidemia
Introduction
Patients with type 2 diabetes mellitus (T2DM) are at
increased risk for atherosclerotic cardiovascular disease
(CVD) and associated morbidity and mortality [1]. This is
likely attributable to a common clustering of CVD risk
factors underlying insulin resistance including dyslipide-
mia, hypertension, hyperglycemia, and a prothrombotic/
proinflammatory state [2]. The characteristic dyslipidemic
profile seen in patients with T2DM includes elevated
triglycerides (TG), low levels of high-density lipoprotein
cholesterol (HDL-C), and modestly elevated levels of low-
density lipoprotein cholesterol (LDL-C), with an increased
number of small dense LDL particles [3–5].
The National Cholesterol Education Program (NCEP)
Adult Treatment Panel III (ATP III) recommends that
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Published online: 21 December 2010patients with DM achieve as a primary target of therapy an
LDL-C<100mg/dLandasasecondarytargetoftherapyanon-
HDL-C <130 mg/dL if hypertriglyceridemia (TG ≥200 mg/dL)
is present [6]. Additionally, the American Diabetes Associa-
tion has recommended optimal values for TG of <150 mg/dL
a n df o rH D L - Co f> 4 0m g / d Li nm e na n d> 5 0m g / d Li n
women [7]. A consensus statement on lipoprotein manage-
ment from the ADA and the American College of Cardiology
specified non-HDL-C and apolipoprotein B (ApoB) treatment
goals of <130 mg/dL and <90 mg/dL, respectively, in patients
with DM [3]. In the presence of DM and at least one
additional major CVD risk factor, more aggressive goals
apply [3, 8].
Although therapeutic lifestyle changes may constitute
initial therapy for patients with T2DM and lipoprotein
abnormalities, most patients also will likely require phar-
macotherapy to achieve lipid targets [2]. Statin monotherapy,
appropriately, is often the initial therapy of choice; however,
maximally tolerated doses of statins often fail to achieve
desired lipid targets beyond LDL-C, and treatment combin-
ing a statin with another lipid-modifying agent may be
required [7, 9]. One such therapeutic approach is to combine
a statin with fenofibric acid (FA). Fenofibric acid choline salt
formulated as enteric-coated mini-tablets in a delayed-release
capsule is approved for combined use with a statin to reduce
TG and increase HDL-C in patients with mixed dyslipidemia
and coronary heart disease (CHD) or a CHD risk equivalent,
who are on optimal statin therapy to achieve their LDL-C
goal.
Two controlled clinical studies of patients with mixed
dyslipidemia evaluated the efficacy and safety of combina-
tion therapy with rosuvastatin (R) 5, 10 or 20 mg + FA for
12 weeks compared with individual monotherapies [10,
11]. In both studies, treatment with R (at each dose) + FA
was found to be efficacious and generally well tolerated.
We present here the results of a post hoc analysis on
achievement of individual and combined lipid and lipoprotein
targets with R 5, 10, or 20 mg + FA combination therapy
compared with corresponding-dose R monotherapies in the
subset of patients with T2DM from the aforementioned two
studies.
Patients and methods
Patients
This analysis includes patients with T2DM from two phase
3, randomized, controlled studies that compared the
efficacy and safety of combination therapy with R 5 mg +
FA 135 mg (Study 1; NCT00463606) and R 10 or 20 mg +
FA 135 mg (Study 2; NCT00300482) to FA and
corresponding-dose R monotherapies in patients with
mixed dyslipidemia [10, 11]. The studies randomized
patients at 349 sites in North America. The protocol for
each study was approved by appropriate ethics committees
and review boards, and all patients provided written
informed consent.
Men and nonpregnant women ≥18 years of age with
fasting lipid results of TG ≥150 mg/dL, HDL-C <40 mg/dL
for men or <50 mg/dL for women, and LDL-C ≥130 mg/dL
were included in each study. Patients with hemoglobin
A1c ≤10.5% in Study 1 and ≤8.5% in Study 2 were
included. Additional eligibility criteria have been published
[12].
Study design
In Study 1, eligible patients were randomized in a double-
blind 1:1:1 ratio to R 5 mg, FA 135 mg, or R 5 mg + FA
135 mg [10]. In Study 2, eligible patients were randomized
in a double-blind 2:2:2:2:2:1 ratio to R 10 or 20 mg, FA
135 mg, R 10 or 20 mg + FA 135 mg, or R 40 mg [11]. The
R 40 mg group was included in Study 2 as a reference for
efficacy and safety assessments and except for comparisons
of baseline characteristics was not included in any statistical
comparisons. Study design was identical in both studies
except for the R dose(s) used. All drugs were self-
administered once daily at approximately the same time of
day with or without food. In both studies, randomization
was stratified by diabetic status and screening TG level
(≤250 mg/dL or >250 mg/dL). Diagnosis of T2DM was
based on the investigators’ assessment of medical history
and/or fasting glucose measurement at screening. Patients
and site and sponsor personnel were blinded to lipid
parameter results obtained after the baseline visit.
Both studies consisted of a 6-week diet/lipid-altering
medication washout screening period, a 12-week treat-
ment period, and a 30-day safety evaluation period.
Patients stopped any lipid-altering medications and were
expected to follow the American Heart Association diet
[13]. A week before randomization, fasting (≥12 h) blood
lipid profiles were obtained to determine eligibility.
Additional fasting blood samples for efficacy analyses
were obtained at the randomization visit, two interim visits
(weeks 4 and 8 of the treatment period), and the final visit
(week 12 or earlier for premature discontinuation).
Samples were analyzed at Covance Central Laboratory
Services (Indianapolis, IN, USA). Additional study details
have been published [10–12].
Statistical analysis
Data collected for patients with a diagnosis of T2DM at
randomization from the two studies were included in this
analysis; only data from the FA monotherapy group were
48 Cardiovasc Drugs Ther (2011) 25:47–57integrated across the two studies. Of a total of 2197 patients
randomized in the two studies, 498 (23%) had T2DM and
were treated.
Last observation carried forward method was used to
impute values for patients with missing postbaseline values.
The number and percentage of patients attaining individual
lipid targets of LDL-C <100 mg/dL, HDL-C >40 mg/dL
(men) or >50 mg/dL (women), TG <150 mg/dL, non-HDL-
C <130 mg/dL, and ApoB <90 mg/dL, and the combined
lipid target of two (LDL-C and non-HDL-C), three (LDL-
C, HDL-C, and TG), and five (LDL-C, HDL-C, TG, non-
HDL-C, and ApoB) parameters at the final visit were
compared between each combination-therapy group and the
corresponding-dose R monotherapy group using Fisher’s
exact test. Patients were not required to have a
corresponding baseline value for the summaries of lipid
targets. As a sensitivity analysis, a logistic regression
analysis of each individual lipid target, in which treatment
group and the corresponding baseline value were included
as independent variables in the model, was performed.
Statistical comparisons of percent changes in lipid and
nonlipid parameters were performed as previously de-
scribed [11]. For HDL-C, TG, ApoB, and high-sensitivity
C-reactive protein (hsCRP), R + FA was compared with
corresponding-dose R monotherapy (primary comparison);
for LDL-C, the primary comparison was with FA mono-
therapy. For non-HDL-C, the primary comparisons were
between R + FA and FA, followed by a comparison with
the corresponding-dose R monotherapy. Data were
analyzed using SAS version 8.2 (SAS Institute, Inc., Cary,
NC, USA).
Results
Of 499 patients with T2DM randomized in the two studies,
498 were treated, and 438 completed their respective study
(Fig. 1). A total of 456 patients, excluding the R 40 mg
arm, had postbaseline efficacy data and were, therefore,
included in the analysis evaluating attainment of lipid
targets. Baseline demographic and clinical characteristics
were similar across all groups (Table 1). Overall (including
patients in the R 40 mg group), approximately 70% of
patients were <65 years of age; at least 85% of patients in
each group weighed ≥70 kg. The incidence of comorbid-
ities was consistent with the increased risk for CVD in this
patient population. The most frequently used (>10%
overall) DM medications at baseline included metformin
(51.4%), glipizide (12.9%), pioglitazone (11.2%), and
rosiglitazone (11.4%); no statistically significant differences
were observed among the treatment groups in the frequency
of the most commonly used diabetic medications at
baseline. During the treatment period, metformin was
initiated by one or more patients in each treatment group
except R 10 mg + FA (3.4% overall). Glipizide, pioglita-
zone, and rosiglitazone were initiated by 0.8%, 1.6%, and
0.6% of patients, respectively during the treatment period.
There were no statistically significant differences between
the combination therapy arms and the corresponding
rosuvastatin monotherapy arms in the frequency of initiat-
ing any of these four diabetic medications during the 12-
week treatment period.
Achievement of individual and combined lipid targets
with R + FA combinationt h e r a p ya n dRa n dF A
monotherapies is shown in Figs. 2 and 3. No statistically
significant differences were observed in the proportion of
patients achieving the LDL-C goal of <100 mg/dL between
any combination-therapy group and the corresponding-dose
R monotherapy group. Treatment with R 10 mg + FA
resulted in a significantly higher proportion of patients
achieving their individual HDL-C target (46.8% vs. 20.8%,
P=0.009) than R 10 mg. The individual TG target was
achieved by a significantly higher proportion of patients
treated with R 10 mg + FA (60.0% vs. 34.0%, P=0.02) and
R 20 mg + FA (54.0% vs. 26.4%, P=0.005) versus the
corresponding-dose R monotherapies. The differences for
the proportion of patients who achieved the individual non-
HDL-C target (55.1% vs. 36.4%, P=0.04) and the
individual ApoB target (58.0% vs. 36.4%, P=0.02) were
significant between R 5 mg + FA and R 5 mg. The
combined target of LDL-C and non-HDL-C was achieved
by 49.3% of patients treated with R 5 mg + FA versus
34.8% of patients treated with R 5-mg monotherapy (P=
0.12) and by 70.2% of patients treated with R 20 mg + FA
versus 66.7% of patients treated with R 20-mg monotherapy
(P=0.83). Treatment with R 10 mg + FA resulted in a
significantly higher proportion of patients achieving the
combined target of LDL-C, HDL-C, and TG (28.3% vs.
8.3%, P=0.02) versus R 10 mg. Similarly, combination
therapy with R 10 mg + FA resulted in a significantly higher
proportion of patients achieving the combined target of all
five parameters (26.1% vs. 8.3%, P=0.03) versus R 10 mg
(Fig. 3). The results of sensitivity analyses adjusting for the
baseline value were similar. In addition to the statistically
significant differences noted above for the individual targets,
sensitivity analyses demonstrated statistically significant
differences favoring R 5 mg + FA versus R 5 mg for the
HDL-C target (odds ratio: 2.2; 95% CI: 1.0, 4.6; P=0.04),
and favoring R 10 mg versus R 10 mg + FA for the LDL-C
target (odds ratio: 0.4; 95% CI: 0.1, 1.0; P=0.05).
R + FA combination therapy resulted in statistically
significant greater mean percent increases in HDL-C
(25.5% vs. 17.0%, P=0.02 for R 5 mg + FA and 19.6%
vs. 5.7%, P=0.002 for R 10 mg + FA) compared with R 5-
or 10-mg monotherapies, respectively (Table 2). All three
doses of R + FA resulted in statistically significant greater
49 Cardiovasc Drugs Ther (2011) 25:47–57mean percent decreases in TG (39.9% vs. 23.6%, P<0.001
for R 5 mg + FA; 44.8% vs. 28.6%, P=0.002 for R 10 mg +
FA; and 42.6% vs. 26.9%, P=0.002 for R 20 mg + FA)
than corresponding dose of R. Compared with R 5 mg,
reductions in non-HDL-C (41.1% vs. 33.5%, P=0.004) and
ApoB (34.9% vs. 28.1%, P=0.008) were significant with R
5 mg + FA, but not with the higher doses of R + FA versus
corresponding-dose R monotherapies.
The safety profile of combination therapy with R + FAwas
consistent with the profiles of the individual monotherapies,
and there were no unexpected adverse effects. Adverse events
(AEs) were the most frequent reason cited for discontinuation
in all groups. The incidence of discontinuations attributed to
AEs was higher with combination therapy than with FA
monotherapy or corresponding dose R monotherapy (Fig. 1).
The incidence of myalgia was similar across treatment
groups, rhabdomyolysis was not reported, and elevations in
creatine phosphokinase were observed infrequently in this
cohort (Table 3). Hepatic-related AEs or laboratory abnor-
malities were rare. Increased creatinine levels were observed
primarily with FA monotherapy and combination therapy
(R 10 or 20 mg + FA; Table 3). Adverse events consistent
with hyperglycemia or increased hemoglobin A1c were
reported infrequently across all treatment groups.
Discussion
This post hoc analysis was performed on pooled data for
the subset of patients with T2DM from two phase 3 studies
that evaluated the lipid-altering efficacy and safety of R +
FA combination therapy in patients with mixed dyslipide-
mia. The primary objective of this analysis was to evaluate
the achievement of individual and combined lipid targets.
In this analysis, a significantly higher proportion of patients
achieved individual targets for HDL-C with R 10 mg + FA,
TG with R 10 or 20 mg + FA, non-HDL-C with R 5 mg +
FA, and ApoB with R 5 mg + FA, compared with
corresponding-dose R monotherapies. The proportion of
patients who achieved the combined target of two lipid
parameters (LDL-C and non-HDL-C) was greater with the
combinations of R 5 mg + FA and R 20 mg + FA than with
the corresponding-dose R monotherapies; these differences
were not statistically significant. The proportion of patients
who achieved the combined target of three lipid parameters
(LDL-C, HDL-C, and TG) and five lipid parameters (LDL-C,
HDL-C, TG, non-HDL-C, and ApoB) was 3-fold greater and
statistically significant with R 10 mg + FAversus R 10 mg; R
10 mg + FA had the highest incidence of patients attaining the
combinedtargetofthreeandfiveparameterscomparedwithR
10 mg (28.3% vs. 8.3% for three parameters and 26.1% vs.
8.3% for five parameters). It is noted that a dose-related
increase in the proportion of patients achieving the combined
target of three and five parameters was not observed with the
combination of R 20 mg + FA, compared with R 10 mg + FA.
The reason for this is unclear, but may be related to the
severity of hypertriglyceridemia in the patients of this study.
Nonetheless, the R 20 mg + FA combination may be required
forpatientsinclinicalpracticewhorequireahigherstatindose
in order to reach their individual LDL-C target, in addition to
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Fig. 1 Patient flowchart.
aThe R 40 mg group was not included in
predefined statistical comparisons.
bPatients may have been counted
for more than one reason for discontinuation.
cOther reasons for
discontinuation included: FA: protocol violation and physician
decision; R 5 mg: protocol violation; R 5 mg + FA: error by study
coordinator, patient randomized in error, and physician decision; R
10 mg: personal reason, investigator decision, and physician decision;
R 10 mg + FA: concomitant illness; and R 20 mg + FA: investigator
decision, physician decision, and patient unable to comply with
protocol. FA, fenofibric acid 135 mg; R, rosuvastatin (5, 10, or 20 mg)
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Fig. 2 a–e. Proportion of T2DM patients achieving individual target
of (a) LDL-C <100 mg/dL; (b) HDL-C >40/50 mg/dL in men/women;
(c) TG <150 mg/dL; (d) non-HDL-C <130 mg/dL; and (e) ApoB
<90 mg/dL at final visit. P-values were obtained using Fisher’s exact
test to test for a difference between each rosuvastatin (R) + fenofibric
acid (FA) combination-therapy group and the corresponding-dose R
monotherapy group. ApoB, apolipoprotein B; FA, fenofibric acid
135 mg; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; R, rosuvastatin (5, 10, or 20 mg);
T2DM, type 2 diabetes mellitus; TG, triglycerides
52 Cardiovasc Drugs Ther (2011) 25:47–57fibrate therapy to treat HDL-C and TG abnormalities. In a
separate study of the fixed-dose combination of rosuvastatin
and fenofibric acid in patients with elevated LDL-C but more
modestly elevated TG, a numerically greater proportion of
patients achieved the combined target of five parameters with
rosuvastatin/fenofibric acid 20 mg/135 mg versus 10 mg/
135 mg (50.9% vs. 45.1%) [14].
Because T2DM is designated as a CHD risk equivalent
in the NCEP ATP III guidelines, the primary treatment goal
in patients with T2DM is LDL-C <100 mg/dL. As noted
earlier, guidelines suggest treating other lipid components
in addition to LDL-C to reduce the overall risk of CVD.
Patients with T2DM frequently present with mixed dysli-
pidemia, which is characterized by abnormalities in LDL
particle size, low levels of HDL-C, and elevated levels of
TG. In this patient population, ApoB and LDL particle
concentration more accurately define residual CVD risk and
are stronger predictors of cardiovascular outcome than
LDL-C [15]. In both Study 1 and Study 2, FA, a fibrate that
effectively raises HDL-C and lowers TG, in combination
with R, improved multiple lipid parameters in patients with
mixed dyslipidemia [10, 11].
The achievement of LDL-C goals has been evaluated in
clinical trials of statin monotherapy and combination
therapy [16–23]. In studies in which R was used, given its
efficacy, approximately 80% or more of patients treated
with R monotherapy or combination therapy achieved
LDL-C goals [16, 18, 19, 21–23]. In CORALL, a study
that evaluated LDL-C goal attainment in patients with
T2DM, 82% and 84% of patients treated with R 10 and
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Fig. 3 a–c. Proportion of T2DM patients achieving combined targets
of (a) LDL-C and non-HDL-C; (b) LDL-C, HDL-C, and TG; and (c)
LDL-C, HDL-C, TG, non-HDL-C, and ApoB. Targets were defined as
LDL-C <100 mg/dL, HDL-C >40/50 mg/dL in men/women, TG
<150 mg/dL, non-HDL-C <130 mg/dL, and ApoB <90 mg/dL at final
visit. ApoB, apolipoprotein B; FA, fenofibric acid 135 mg; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; R, rosuvastatin (5, 10, or 20 mg); T2DM, type 2 diabetes
mellitus; TG, triglycerides
53 Cardiovasc Drugs Ther (2011) 25:47–5720mg, respectively, achieved the LDL-C goalof<100mg/dL
at 24 weeks of treatment [23]. Although there were differ-
ences in study design and duration of treatment, the goal
attainment results of the CORALL study are similar to the
proportion of patients who achieved LDL-C goals with R 10
and 20 mg monotherapy in the present analysis. The
proportions of T2DM patients who achieved the LDL-C
goal of <100 mg/dL in the present studies with R + FA
combination therapy were slightly lower than the proportions
who achieved this goal with corresponding-dose R mono-
therapies. This is not surprising, because it has been shown
that treatment with fibrates results in either a small increase
or no change in the measured LDL-C content in patients
with high TG and low HDL-C levels, likely because of
accelerated fibrate-induced catabolism of TG-rich very-low-
density lipoprotein (VLDL) particles [24–26]. Treatment
Table 2 Percent change from baseline to final visit in efficacy parameters
Variable FA 135 mg R 5 mg R 5 mg + FA R 10 mg R 10 mg + FA R 20 mg R 20 mg + FA
HDL-C n=114 n=66 n=69 n=46 n=45 n=49 n=46
Baseline mean, mg/dL 39.3 41.1 40.3 36.8 38.4 37.7 38.6
Final mean, mg/dL 46.5 46.3 49.2 39.3 46.1 41.1 44.5
Mean change, % (SE) 19.0 (2.03) 17.0 (2.68) 25.5 (2.61) 5.7 (3.20) 19.6 (3.24) 11.0 (3.10) 16.4 (3.19)
P-value
a 0.02
c 0.002
c 0.22
c
TG n=118 n=66 n=69 n=50 n=50 n=53 n=50
Baseline mean, mg/dL 272.8 311.2 306.7 320.8 304.0 300.4 285.4
Final mean, mg/dL 164.6 207.0 157.5 218.5 169.1 195.2 152.0
Mean change, % (SE) −34.5 (2.41) −23.6 (3.20) −39.9 (3.13) −28.6 (3.68) −44.8 (3.68) −26.9 (3.57) −42.6 (3.68)
P-value
a <0.001
c 0.002
c 0.002
c
LDL-C n=116 n=66 n=69 n=49 n=46 n=51 n=47
Baseline mean, mg/dL 154.4 147.9 146.6 147.2 143.9 151.9 152.9
Final mean, mg/dL 142.1 102.4 95.7 83.9 91.3 81.6 91.9
Mean change, % (SE) −5.2 (1.67) −28.1 (2.22) −32.8 (2.17) −43.3 (2.57) −36.8 (2.67) −44.3 (2.52) −37.0 (2.63)
P-value
a <0.001
d <0.001
d <0.001
d
Non-HDL-C n=114 n=66 n=69 n=46 n=45 n=49 n=46
Baseline mean, mg/dL 218.2 217.8 218.3 217.4 213.9 222.5 216.3
Final mean, mg/dL 178.3 144.6 124.9 121.8 120.7 118.5 117.0
Mean change, % (SE) −17.5 (1.41) −33.5 (1.86) −41.1 (1.82) −44.6 (2.22) −43.6 (2.26) −45.8 (2.16) −44.9 (2.23)
P-value
a <0.001
d <0.001
d <0.001
d
0.004
c 0.77
c 0.77
c
ApoB n=116 n=66 n=69 n=49 n=50 n=52 n=50
Baseline mean, mg/dL 138.8 133.7 131.5 144.7 141.2 146.1 142.9
Final mean, mg/dL 117.9 97.7 86.6 90.3 88.6 88.7 87.8
Mean change, % (SE) −14.8 (1.37) −28.1 (1.82) −34.9 (1.79) −36.3 (2.11) −36.2 (2.09) −37.2 (2.05) −36.2 (2.08)
P-value
a 0.008
c 0.97
c 0.75
c
hsCRP n=117 n=66 n=69 n=49 n=50 n=52 n=50
Baseline median, mg/L 2.88 3.50 3.43 3.90 3.94 3.24 3.96
Final median, mg/L 2.62 2.82 2.37 2.42 2.71 2.14 2.55
Median change, % −7.2 −11.5 −26.8 −31.1 −28.0 −34.2 −40.7
P-value
b 0.20
c 0.52
c 0.99
c
FA fenofibric acid; R rosuvastatin; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; TG triglycerides;
ApoB apolipoprotein B; hsCRP high-sensitivity C-reactive protein. Only patients with both baseline and at least one postbaseline value were
included in this analysis.
aP-value is from an analysis of covariance with the corresponding baseline value as the covariate and with effects for treatment group and screening TG
level (≤250 mg/dL, >250 mg/dL).
bP-value is from the van Elteren’s test with screening TG level as stratum.
cP-value for difference between R + FA group and corresponding-dose R monotherapy group.
dP-value for difference between R + FA group and FA monotherapy group.
54 Cardiovasc Drugs Ther (2011) 25:47–57with fibrates also results in a shift in LDL particle size from
a small and dense to a larger phenotype [27–29].
Attainment of the LDL-C goal is just one component of
the recommended lipid profile for patients with T2DM. In
order to reduce CVD risk, these patients must also increase
HDL-C levels and decrease TG levels [30–33]. In this
analysis of the two controlled studies, patients with T2DM
showedsignificantlygreatermeanpercentchangesinLDL-C,
HDL-C, TG, non-HDL-C, and ApoB with R 5 mg + FA;
LDL-C,HDL-C,andTGwithR 10mg+ FA;andLDL-Cand
TG with R 20 mg + FA, compared with prespecified
monotherapies.
The results of this analysis are supported by the findings
reported in a study comparing the efficacy of R 5 or 10 mg
+ fenofibrate combination therapy with that of each
monotherapy component in patients with T2DM who had
high levels of TG and total cholesterol at baseline [34]. In
that study, decreases in TG levels of 34% and 30% and
changes in LDL-C of +1% and −47% were achieved after
24 weeks of treatment with fenofibrate monotherapy and R
monotherapy, respectively. Administration of R 10 mg +
fenofibrate resulted in a 47% decrease in TG, which was
significantly greater (P=0.001) than that seen with R
monotherapy.
The ACCORD (Action to Control Cardiovascular Risk
in Diabetes) Lipid component of the overall ACCORD trial
was designed to test whether CVD event reduction with the
combination of a statin and a fibrate would exceed what is
achieved with statin monotherapy in patients with T2DM. It
should be noted that although the combination of simvas-
tatin and fenofibrate in the ACCORD Lipid study did not
significantly reduce the rate of nonfatal myocardial infarc-
tion, nonfatal stroke, or cardiovascular death compared with
simvastatin alone, a prespecified analysis demonstrated in
patients with both high TG (≥204 mg/dL) and low HDL-C
(≤34 mg/dL) a 31% relative risk reduction in cardiovascular
events with combination therapy compared with the
monotherapy group [35]. Furthermore, the ACCORD Eye
study, which evaluated the progression of diabetic retinop-
athy in a subgroup of patients from the ACCORD study
found that treatment with simvastatin and fenofibrate
resulted in a significant 40% reduction in the progression
of diabetic retinopathy versus simvastatin monotherapy
[36].
Combination therapy with R + FA was generally well
tolerated in the subgroup of patients with T2DM. The
safety profile of R + FA combination therapy was
consistent with that of each monotherapy. Although, the
risk for increased muscle-related AEs is a safety concern
when combining fibrates with statins, the incidence of
myalgia was lower with R 5 or 10 mg + FA, compared with
the corresponding-dose R monotherapy, and there were no
reports of rhabdomyolysis in this analysis. Similarly, the
ACCORD Lipid study found no increased risk for muscle-
related AEs with simvastatin and fenofibrate combination
treatment for up to 4.5 years compared with simvastatin
alone [35]. Elevations in liver enzymes were infrequent
occurrences in the present analysis and abnormal creatinine
values were observed predominantly with FA monotherapy
and combination therapy.
Table 3 Adverse events and laboratory variables related to muscle, hepatic, and renal function
Adverse events and laboratory variables FA 135 mg
(n=123)
R5m g
(n=68)
R 5 mg + FA
(n=73)
R1 0m g
(n=52)
R1 0m g+F A
(n=52)
R2 0m g
(n=53)
R2 0m g+F A
(n=52)
Muscle-related
Myalgia, n (%)
a 3 (2.4) 2 (2.9) 1 (1.4) 3 (5.8) 1 (1.9) 1 (1.9) 2 (3.8)
CK increased, n (%)
a 4 (3.3) 0 2 (2.7) 1 (1.9) 0 2 (3.8) 0
CK >5× ULN, n/N (%) 0/119 0/68 0/71 0/50 1/51 (2.0) 0/53 0/51
CK >10× ULN, n/N (%) 0/119 0/68 0/71 0/50 1/51 (2.0) 0/53 0/51
Hepatic-related
ALT >5× ULN, n/N (%) 0/119 0/68 1/71 (1.4) 0/50 0/50 0/53 0/51
Renal-related
Creatinine increased, n (%)
a 3 (2.4) 0 0 0 1 (1.9) 0 3 (5.8)
Creatinine ≥50% increase from baseline
and >ULN, n/N (%)
12/119 (10.1) 0/68 1/71 (1.4)
b 2/50 (4.0) 2/50 (4.0) 0/53 2/51 (3.9)
Creatinine ≥100% increase from
baseline, n/N (%)
1/119 (0.8) 0/68 0/71 0/50 0/50 0/53 0/51
Creatinine >2 mg/dL, n/N (%) 8/119 (6.7) 0/68 0/71
b 1/50 (2.0) 2/50 (4.0) 0/53 1/51 (2.0)
FA fenofibric acid; R rosuvastatin; CK creatine phosphokinase; ULN upper limit of normal; ALT alanine aminotransferase; MedDRA Medical
Dictionary for Regulatory Activities.
aMedDRA Version 11.1 preferred term.
bP<0.05 for comparison between R + FA group and FA monotherapy group using Fisher’s exact text.
55 Cardiovasc Drugs Ther (2011) 25:47–57The major limitations for application of these results to
clinical practice are attributable to constraints of study design.
Combination therapy with R + FAwas initiated in the studies
thatprovideddataforthisanalysis,whereasinclinicalpractice
statin monotherapy is often initiated first with FA added to the
regimen if treatment goals are not met or if further titration of
the statin is contraindicated. Although the duration of
treatment, which was limited to 12 weeks in these studies,
was sufficient to demonstrate efficacy, it probably is not an
accurate reflection of full treatment effect in clinical practice.
The results of a long-term clinical trial in which patients with
mixed dyslipidemia, who completed Study 2, received R
20 mg + FA for 52 weeks confirmed additional benefit with a
longer duration of combination treatment [37].
Despite these limitations, this analysis clearly demon-
strated the effectiveness and safety of R + FA combination
therapy in attaining individual and combined lipid targets in
patients with T2DM, compared with R monotherapy.
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